Overview of the government policy of the Pharmaceutical Industry in Indonesia and possible impact to the business
ACI is pleased to announce that Widyaretna Buenastuti, Public Affairs & Communications Director,Pfizer Indonesia will give a presentation at International Pharma Regulatory Summit, 27th-28th July 2017 in Singapore
Presentation Title:Overview of the government policy of the Pharmaceutical Industry in Indonesia and possible impact to the business
Speaker:Widyaretna Buenastuti, Public Affairs & Communications Director,
If you have any questions for the speaker, please write to us and we would discuss at the summit
Widya started as Public Affairs and Communications Director of Pfizer in 2011. Prior to that, Widya was the Legal Director for Pfizer Indonesia and had given Legal services since 2002 where she joined Pfizer as Legal Manager. During her tenure in Legal, she had a one year experience of managing legal affairs of Pfizer Singapore (2010 – 2011).
In her current role, one of her responsibility is to ensure Pfizer’s good reputation in the eye of its stakeholders be maintained. In addition to her roles in Pfizer, she has been asked by the external stakeholders to also take part and lead the Indonesian Anti-Counterfeiting Society or known in Indonesia abbreviation as MIAP. She holds the chairmanship of this association since 2008 and since then has increased the awareness from the stakeholders to jointly combat counterfeit. Various partnerships with stakeholders have been built up under her initiative in order to carry out Pfizer’s objectives such as in the area of Intellectual Property Rights and related health policy.
Widya’s legal degree was obtained from Faculty of Law of the University of Indonesia and her master degree in Strategic Management from Prasetiya Mulya Business School, Jakarta. Currently she has been admitted in a Doctoral Program in Law at University of Pelita Harapan, Indonesia. She has also published an inspirational book of her own in 2015.
Early Confirmed Speakers:
Widyaretna Buenastuti, Public Affairs & Communications Director, Pfizer Indonesia
May Ng, Regulatory And Quality Consultant,Founder, ARQon Pte Ltd
Regulatroy submissions implementation in eCTD format
The ASEAN Labelling Harmonisation Effort
Registration and approval timeline – combination products and exemptions
What’s new with clinical regulatory requirements in Asia Pacific?
Global trends vs. specific region’s updates for pharmacovigilance
Regulatory affairs support in providing advices to commercial team for inspection
Global Guidelines for the Development of Biologics
Effectively interpret complicated regulatory guidelines to fast track your drug approval process
Asia’s regulatory systems are diverse, and oftentimes challenging to navigate. The regulatory agency in each Asian country has its own set of regulations and customary manner of conducting business. Thus, determining the most effective and efficient strategy to obtain approval for your pharmaceutical product from each regulatory body without sufficient knowledge and experience with Asian regulatory affairs can be a very difficult task.